Comparative Pharmacology
Head-to-head clinical analysis: BETAGAN versus BETAPACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAGAN versus BETAPACE.
BETAGAN vs BETAPACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-1 selective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Instill 1 drop of 0.25% or 0.5% solution into the affected eye(s) twice daily.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in renal impairment (up to 30 hours).
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Primarily renal excretion of unchanged drug and metabolites; about 80% eliminated in urine, 20% in feces as unchanged drug or glucuronide conjugates.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Category C
Category C
Beta-Blocker
Beta-Blocker